Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The only news in that video that hasn't been talked about here is the claim they're hiring people for the sawston facility or perhaps I missed it. Or, possibly they're wrong. Can anyone substantiate that?
So we should assume there was no conference call scheduled this morning?
Sustaining a higher stock price might be difficult because it will be some months before the FDA approves the drug. A reverse split on good news will ensure the stock price stays high enough to qualify for listing. I believe there are restrictions on some institutional investors buying stock below $5 as well.
Relief Therapeutics Holding expects top-line data from a trial of RLF-100 used intravenously in patients with COVID-19 to be released this month, the Swiss company said on Monday.
"The statistical analysis of the data remains ongoing. Relief expects top-line data from this trial to be reported once the required statistical analyses have been completed," it said, while affirming that collaboration partner NeuroRx Inc has initiated a phase 2/3 clinical trial investigating the role of inhaled RLF-100TM for treating of patients with severe COVID-19.
https://whbl.com/2021/02/08/relief-therapeutics-says-data-from-covid-drug-trial-to-emerge-this-month/
South Africa halts AstraZeneca vaccine over new strain
https://www.bbc.com/news/world-africa-55975052
With no insight posted here all I can say is watch the Swiss market tomorrow. The price action might give a clue.
Sounds to me like you think the trial failed and that's what the call is about tomorrow. I'm just guessing since you haven't really explained why you're so pessimistic.
It has been mentioned here before that the trial results may not yield a p value that might be expected based on the success in the the open trial results. Those patients in the open trial were near death and the phase 3 trial patients were not as sick, hence more in the placebo group could be expected to get better on their own which would reduce the p value overall. I'm prepared to see a p value that's not spectacular even if it does indicate statistical significance. Fingers crossed that's not the case and the results are indeed spectacular.
I hope you're wrong but unfortunately can't disagree with you. An eua for rlf100 would be a serious blow to the vax pharmas. We'll soon see the results and if they're as good as we all hope and we don't get the eua designation we'll know that therapeutics have been completely sidelined in favor of BP profits.
Going vertical on no news and average volume. Not getting excited here until some news confirms the runup.
News after the close today. Let's the news percolate over the weekend. Anyway, that's my story and I'm sticking to it.;)
This is from the article.
In a January 26 preprint paper, for example, researchers demonstrated that the SARS-CoV-2 variant that emerged in South Africa was "markedly more resistant" to antibodies in convalescent plasma, and "completely or markedly abolished" the activities of Lilly's bamlanivimab and Regeneron's casirivimab on their own. But Regeneron's imdevimab appeared to retain its function.
The last part of the report indicates two out of three of the drugs are not effective against the new mutated strains.
New COVID-19 Monoclonal Antibody Data Could Shift Clinical Practice
https://www.medscape.com/viewarticle/945136?src=mkm_covid_update_210203_MSCPEDIT&uac=209822AX&impID=3170928&faf=1
I think brpau is set to rake in the lions share of the credit for a successful trial via Neurorx because neurorx will be making the pr announcements. The disparity in their price action vs rlftf is telling.
An increase in capital gains taxes to their former levels or perhaps higher is definitely in the works. Do you think that would affect the market?
Brpa is doing very well according to this report and afaik it's only because of rlf 100.
https://www.google.com/amp/s/www.investorsobserver.com/news/stock-update/amp/is-big-rock-partners-acquisition-corp-brpa-stock-near-the-top-of-the-shell-companies-industry
On the other hand, the administration is talking about taxing paper gains in your portfolio. An absurd idea that likely won't pass but you never know. Socialism is trending.
I've actually changed my mind somewhat regarding whether or not redditors can influence this stock. An article I posted here a few minutes ago says redditors are starting to move to other platforms that allow trading otc and their reason for doing so is to take down Adam Feuerstein and other stock "analysts" who routinely set out to drive stock prices down. Right now, the redditors primary target stock is cydy.NWBO is mentioned as a buyers target and rlftf is mentioned but only in passing. So, yeah, we could potentially see some buying activity from activists. The article is well worth the read.
This is up on the nwbo board. A very interesting read and rkftf is mentioned in a footnote.
https://insiderfinancial.com/reddit-rebellion-targeting-the-short-mafia-next/180939/
Redditors mostly use robin hood.They can't buy otc there. Hoping for a redditor style takedown here is absurd.
Still going up though. Volume is picking up too. Whatever is happening on the US side isn't reflective of bad news imo.
FYI. It's up on the Swiss exchange and the drop in price here hasn't affected the Swiss price.
Given recent statements I think it has to be sometime this week or something is amiss. Maximum impact for the stock price would be Friday after markets close but for patients, the sooner the better.
I believe neurorx will be the primary beneficiary of the news through its merger partner. They will be the ones releasing the trial data. Relief will go up of course but not as much.
I'm actually pleased with today's price action, up to now anyway. It's steadily building off the share price from yesterday before the spike. I considered the spike an anomaly and this gradual move up has a better foundation. Hope it continues into the close.
Just saying your valuation is incorrect. Way off in fact. But you go with that.
Most of the revenue will come from the US.
Not all of that revenue goes to relief. A large percentage would go to neurorx.
Yes. That's fine. On the other hand, practically no one is dying from the flu anymore so it's a wash.
There's ivermectin. Also hydroxychloroquine is back in the good graces of the cdc now that the election is over. Both are cheap and effective.
A quote, probably apocryphal, attributed to Wyatt Earp when asked about gunfighting. Take your time but be quick about it.
As scary as your analysis is all that I could think of was a line from Ghostbusters. Thats just the way my mind works. Shuns and Zuuls will be roasted today.
Gozer the Traveller, he will come in one of the pre-chosen forms. During the rectification of the Vuldronaii, the Traveller came as a large and moving Torb! Then, during the third reconciliation of the last of the Meketrex Supplicants they chose a new form for him... that of a Giant Sloar! Many Shubs and Zuuls knew what it was to be roasted in the depths of the Sloar that day I can tell you."
Whatever happened on the US side yesterday wasn't because of fundamentals or news. The run up ended as quickly as it began and the share price kept pulling back right into the close. The Swiss market is telling you something. I'm hoping we stay in the 50s today.
Aand, it's coming right back down.
Going vertical but the volume doesn't indicate a news leak. Just speculation I think.
Relief Will Acquire Rights to Potential Sarcoidosis Therapy RLF-100 in Deal
https://sarcoidosisnews.com/2021/01/28/deal-gives-relief-therapeutics-intellectual-rights-potential-sarcoidosis-therapy-rlf-100/
Probably just the expected pull back after the 8K disappointment.